Inactivation of HIV in blood

Öhagen, Åsa; Gibaja, Veronica; Aytay, S.; Horrigan, Jeff; Lunderville, Douglas; Lazo, Aris

doi:10.1046/j.1537-2995.2002.00217.x

Cited by 22 publications

(19 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most inactivation approaches use chemicals that bind nucleic acids either directly (40) or when subjected to UV light (16), preventing viral replication. The toxicity and mutagenicity of these chemicals raise significant concern.…”

Section: Discussionmentioning

confidence: 99%

Deactivation of Human Immunodeficiency Virus Type 1 in Medium by Copper Oxide-Containing Filters

Borkow

Lara

Covington

et al. 2008

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Human immunodeficiency virus type 1 (HIV-1) can be transmitted through breast-feeding and through contaminated blood donations. Copper has potent biocidal properties and has been found to inactivate HIV-1 infectivity. The objective of this study was to determine the capacity of copper-based filters to inactivate HIV-1 in culture media. Medium spiked with high titers of HIV-1 was exposed to copper oxide powder or copper oxide-impregnated fibers or passed through copper-based filters, and the infectious viral titers before and after treatment were determined. Cell-free and cell-associated HIV-1 infectivity was inhibited when exposed to copper oxide in a dose-dependent manner, without cytotoxicity at the active antiviral copper concentrations. Similar dose-dependent inhibition occurred when HIV-1 was exposed to copper-impregnated fibers. Filtration of HIV-1 through filters containing the copper powder or copper-impregnated fibers resulted in viral deactivation of all 12 wild-type or drug-resistant laboratory or clinical, macrophage-tropic and T-cell-tropic, clade A, B, or C, HIV-1 isolates tested. Viral inactivation was not strain specific. Thus, a novel means to inactivate HIV-1 in medium has been developed. This inexpensive methodology may significantly reduce HIV-1 transmission from “mother to child” and/or through blood donations if proven to be effective in breast milk or plasma and safe for use. The successful application of this technology may impact HIV-1 transmission, especially in developing countries where HIV-1 is rampant.

show abstract

Section: Discussionmentioning

confidence: 99%

Deactivation of Human Immunodeficiency Virus Type 1 in Medium by Copper Oxide-Containing Filters

Borkow

Lara

Covington

et al. 2008

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…To broaden the spectrum of pathogens inactivated by PEN110, Laso and colleagues extended the 22 ± 2°C incubation period to 22 ± 2 h [41]. Under these conditions, ≥ 5·5 log 10 of Sindbis virus, ≥ 6·3 log 10 of VSV, ≥ 6·4 log 10 of BVDV, ≥ 6·5 log 10 of PRV, ≥ 6·0 log 10 of PPV, ≥ 6·5 log 10 of reovirus 3, ≥ 4·7 log 10 of Adenovirus‐2, ≥ 6·6 log 10 of vesicular exanthema of swine virus, ≥ 6·7 log 10 of foot and mouth disease virus, ≥ 6·7 log 10 of bluetongue virus, ≥ 7 log 10 of WNV, ≥ 5 log 10 DHBV, as well as ≥ 5·57 log 10 of extracellular HIV‐1 and ≥ 4·5 log 10 of cell‐associated HIV were inactivated [41–44]. Other studies demonstrated complete prevention of the outgrowth of 10–100 CFU/ml of Yersinia enterocolitica , Pseudomonas fluorescens and Pseudomonas putida during 42 ‐day storage of RBCs treated with 0·1% PEN110 for 24 h [45] and inactivation of ≥ 5·6 log10 of Acinetobacter lwoffii , ≥ 6·1 log 10 Acinetobacter johnsonii , ≥ 4 log 10 of Clostridium perfringens and ≥ 5 log 10 of Proprionibacterium acnes [46].…”

Section: Akylating Agentsmentioning

confidence: 99%

Developing pathogen reduction technologies for RBC suspensions

Wagner

2010

Vox Sanguinis

View full text Add to dashboard Cite

Numerous studies have evaluated a wide variety of photosensitizers and alkylating agents as candidates for a pathogen reduction process to be used in RBC suspensions. The methodologies that produce robust inactivation of pathogens with maintenance of RBC properties during storage involve those that specifically target nucleic acids. This has been demonstrated through in vitro studies by flexible photosensitizers, which specifically target nucleic acid but do not engage in photochemistry when free in solution and nucleic acid alkylating agents in conjunction with extracellular quencher(s) to protect against RBC membrane alkylation. The flexible photosensitizer method must be scaled up to entire units, and toxicology studies would need to be performed for further development. Clinical trials will ultimately be necessary to further develop either flexible photosensitizers or nucleic acid alkylating methods with quenchers for use in Transfusion Medicine.

show abstract

“…[85][86][87] The INACTINEs are stable monoalkylators that are immediately active upon addition to blood or red cell concentrates (Fig. INACTINE (PEN 110), a nucleic acid-targeted compound, was reported to inactivate viruses, bacteria, and leukocytes in red cell suspensions.…”

Section: Potential Systems For Inactivation Of Pathogens In Red Cell mentioning

confidence: 99%

Virus-Safe Products: Pathogen Reduction and Inactivation

Corash¹

2007

Blood Banking and Transfusion Medicine

View full text Add to dashboard Cite

Inactivation of HIV in blood

Abstract: These results suggest that PEN110 inactivates HIV-1 by targeting the viral nucleic acid.

Cited by 22 publications

References 48 publications

Deactivation of Human Immunodeficiency Virus Type 1 in Medium by Copper Oxide-Containing Filters

Deactivation of Human Immunodeficiency Virus Type 1 in Medium by Copper Oxide-Containing Filters

Developing pathogen reduction technologies for RBC suspensions

Virus-Safe Products: Pathogen Reduction and Inactivation

Contact Info

Product

Resources

About